New Zealand markets open in 4 hours 4 minutes
  • NZX 50

    11,206.93
    -51.37 (-0.46%)
     
  • NZD/USD

    0.6407
    +0.0111 (+1.76%)
     
  • ALL ORDS

    7,303.30
    -123.30 (-1.66%)
     
  • OIL

    111.03
    +1.44 (+1.31%)
     
  • GOLD

    1,839.80
    +23.90 (+1.32%)
     

Immuron Receives AUD $306,154 R&D Tax Concession Refund

·1-min read

MELBOURNE, Australia, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that under the Australian Government’s Research and Development Income Tax Concession incentive program, the Company has received a cash refund of AUD $306,154 for eligible research and development expenditure incurred during the 2021 Financial Year.

This release has been authorized by the directors of Immuron Limited.

COMPANY CONTACT:

Dr Jerry Kanellos, Ph.D.
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com

US INVESTOR CONTACT

Dave Gentry, CEO
RedChip Companies Inc.
+1-407-491-4498
dave@redchip.com

About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.

For more information visit: http://www.immuron.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting